A Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children (P03579)

Stopped Study was terminated early (10 July 2015) based on preliminary analysis of pharmacokinetic data.

Conditions

• Fungal Infections

Interventions

• DRUG: Posaconazole 12 mg/kg/day BID
• DRUG: Posaconazole 18 mg/kg/day BID
• DRUG: Posaconazole 18 mg/kg/day TID
• DRUG: Posaconazole 12 mg/kg/day TID

Sponsor

Merck Sharp & Dohme LLC